[1]World Health Organization.Fact Sheet:Hepatitis B[EB/OL].[http://wwwwhoint/mediacentre/factsheets/fs204/en/.
|
[2]Lee WM.Hepatitis B virus infection[J].N Engl JMed, 1997, 337 (24) :1733-1745.
|
[3]Shepard CW, Finelli L, Alter MJ.Global epidemiologyof hepatitis C virus infection[J].Lancet Infect Dis, 2005, 5 (9) :558-567.
|
[4]Beasley RP, Hwang LY, Lin CC, et al.Hepatocellularcarcinoma and hepatitis B virus.A prospective study of 22707 men in Taiwan[J].Lancet, 1981, 2 (8256) :1129-1133.
|
[5]You SL, Yang HI, Chen CJ.Seropositivity of hepatitis B eantigen and hepatocellular carcinoma[J].Ann Med, 2004, 36 (3) :215-224.
|
[6]Yang HI, Lu SN, Liaw YF, et al.Hepatitis B e antigen andthe risk of hepatocellular carcinoma[J].N Engl J Med, 2002, 347 (3) :168-174.
|
[7]Chen CJ, Yang HI, You SL.Hepatitis B e antigen and therisk of hepatocellular carcinoma (authors reply) [J].N Engl JMed, 2002, 347 (21) :1722.
|
[8]Chen CJ, Iloeje UH, Yang HI.Long-term outcomes inhepatitis B:the REVEAL-HBV study[J].Clin Liver Dis, 2007, 11 (4) :797-816.
|
[9]Chen CJ, Yang HI, Iloeje UH.Hepatitis B virus DNA levelsand outcomes in chronic hepatitis B[J].Hepatology, 2009, 49 (5 Suppl) :s72-84.
|
[10]Chen CJ, Yang HI, Su J, et al.Risk of hepatocellularcarcinoma across a biological gradient of serum hepatitis Bvirus DNA level[J].JAMA, 2006, 295 (1) :65-73.
|
[11]Chen CJ, Iloeje UH, Yang HI.Serum hepatitis B virus DNA asa predictor of the development of cirrhosis and hepatocellularcarcinoma[J].Current Hepatitis Reports, 2007, 6 (1) :9-16.
|
[12]Chen JD, Yang HI, Iloeje UH, et al.Carriers of inactive hepatitisB virus are still at risk for hepatocellular carcinoma and liver-related death[J].Gastroenterology, 2010, 138 (5) :1747-1754.
|
[13]Iloeje UH, Yang HI, Chen CJ.Disease progress of chronichepatitis B virus infection:effects of sustained viralreplication[J].Chinese Hepatology, 2006, 11 (6) :410-412.
|
[14]Iloeje UH, Yang HI, Jen CL, et al.Risk and predictors ofmortality associated with chronic hepatitis B infection[J].ClinGastroenterol Hepatol, 2007, 5 (8) :921-931.
|
[15]Iloeje UH, Yang HI, Su J, et al.Predicting cirrhosis riskbased on the level of circulating hepatitis B viral load[J].Gastroenterology, 2006, 130 (3) :678-686.
|
[16]Liu J, Yang HI, Lee MH, et al.Incidence and determinantsof spontaneous hepatitis B surface antigen seroclearance:a community-based follow-up study[J].Gastroenterology, 2010, 139 (2) :474-482.
|
[17]Yang HI, Sherman M, Su J, et al.Nomograms for risk ofhepatocellular carcinoma in patients with chronic hepatitis Bvirus infection[J].J Clin Oncol, 2010, 28 (14) :2437-2444.
|
[18]Yang HI, Yeh SH, Chen PJ, et al.Associations Between HepatitisB Virus Genotype and Mutants and the Risk of HepatocellularCarcinoma[J].J Natl Cancer Inst, 2008, 100 (16) :1134-1143.
|
[19]Kao JH, Chen DS.HBV genotypes:Epidemiology andimplications regarding natural history[J].Current HepatitisReports, 2006, 5 (1) :5-13.
|
[20]Liaw YF, Chu CM.Hepatitis B virus infection[J].Lancet, 2009, 373 (9663) :582-592.
|
[21]Scott JD, Gretch DR.Molecular diagnostics of hepatitisC virus infection:a systematic review[J].JAMA, 2007, 297 (7) :724-732.
|
[22]Hoofnagle JH.Course and outcome of hepatitis C[J].Hepatology, 2002, 36 (Suppl 1) :s21-29.
|
[23]Simmonds P.Viral heterogeneity of the hepatitis C virus[J].JHepatol, 1999, 31 (Suppl 1) :54-60.
|
[24]Hoofnagle JH, SeeffLB.Peginterferon and ribavirin for chronichepatitis C[J].N Engl J Med, 2006, 355 (23) :2444-2451.
|
[25]McHutchison JG, Everson GT, Gordon SC, et al.Telaprevirwith peginterferon and ribavirin for chronic HCV genotype 1infection[J].N Engl J Med, 2009, 360 (18) :1827-1838.
|
[26]Lee MH, Yang HI, Lu SN, et al.Hepatitis C virus seromarkersand subsequent risk of hepatocellular carcinoma:long-termpredictors from a community-based cohort study[J].J ClinOncol, 2010, 28 (30) :4587-4593.
|